Prs17 - Budget Impact Analysis of the Use of Umeclidinium Bromide/Vilanterol 62.5/25 MCG in the Treatment of Chronic Obstructive Pulmonary Disease in Spain

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2411
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV